www.fdanews.com/articles/120159-cornerstone-to-acquire-rights-to-factive
Cornerstone to Acquire Rights to Factive
September 3, 2009
Cornerstone Therapeutics Inc. announced that it has received the approval of the United States Bankruptcy Court for the District of Massachusetts for its acquisition of the commercial rights to the antibiotic Factive (gemifloxacin mesylate) in North America and certain countries in Europe from Oscient Pharmaceuticals Corporation and expects to promptly close the transaction.
StreetInsider.com
StreetInsider.com